The FDA on March 11, 2016 approved XALKORI® capsules for the treatment of patients with metastatic Non Small Cell Lung Cancer (NSCLC) whose tumors are ROS1-positive. XALKORI® is a product of Pfizer, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
